Nervous Disorder TRIZ Cases

Formula I compounds target cathepsin S protease activity through specific substituent interactions.

Immunogenic alpha-synuclein fragments trigger antibody production to reduce brain protein aggregates.

A pharmaceutical gel composition for intra-intestinal administration combines levodopa with dopamine decarboxylase and catechol-O-methyltransferase inhibitors.

Humanized antibodies bind interferon-alpha subtypes using CDR truncation and back mutations to reduce immunogenicity while maintaining binding affinity.

Modified molecular structures balance brain penetrance and metabolic stability for Parkinson's treatment.

Fluorinated phenyl substituents on indole cores improve binding affinity, resolving inadequate therapeutic relief for circadian rhythm and depression.

Upregulating macrophage MCT1 gene expression accelerates nerve regeneration by enhancing glycolytic activity, overcoming slow conventional repair speeds.

A traditional Chinese medicine composition balances yin and yang to improve sleep quality using synergistic herbal ingredients.

Bioactivation of glucomoringin yields GMG-ITC, which reduces chemotherapy-induced neurotoxicity while maintaining cancer treatment efficacy.

Excipients form thin films on compressed tablets to preserve spherical activated carbon pore structure, reducing administered volume and water intake.

Lactobacillus paracasei LT12 degrades inosine and guanosine to lower blood uric acid levels, reducing renal damage from hyperuricemia.

Fluoroethylnormemantine reduces anxiety via selective NMDA receptor antagonism without drowsiness or psychosis.

A nutritional composition combining DHA, EPA, uridine, and B vitamins enhances membrane function to support daily living activities.

Formula I azaindole compounds inhibit aberrant kinases like LRRK2, addressing limited efficacy and specificity in Parkinson's disease treatments.

Peptide hormone analogues featuring a C-terminal extension sequence to enhance pharmacokinetic stability.

Combining elamipretide and omaveloxolone targets mitochondrial dysfunction and oxidative stress in Friedreich's ataxia therapy.

IGF1R+ mesenchymal stem cells enhance tissue repair through targeted receptor expression.

Modified peptide sequences target B1 and B2 receptors to treat inflammatory diseases and pain while reducing side effects.

AAV-mediated LGI1 overexpression achieves uniform neuronal targeting, resolving uneven infection issues inherent in direct Kv1.1 gene therapy approaches.

Heterogeneous autologous stem cell concentrate infuses directly over the injured spinal cord to promote tissue regeneration.

Mutating Fc region positions 243 and 264 directs yeast host cells to produce antibodies with tailored N-glycan structures.

Sophora flavescens extracts activate alcohol dehydrogenase and acetaldehyde dehydrogenase enzymes to reduce blood alcohol concentration.

Compounds inhibit macrophage migration inhibitor factor nuclease activity to block parthanatos-mediated cell death.

A method alters physiological parameters to approximate elastic collisions within an organism.

PLGA-coated resiniferatoxin nanoparticles deliver ultra-low doses through the skin barrier to treat diabetic peripheral neuropathy without application pain.

Targeting the CD47 IgV domain blocks TSP1 and SIRPalpha binding, resolving specificity trade-offs while enhancing tumor phagocytosis.

Segmented ApoE peptides reduce molecular complexity while maintaining anti-inflammatory efficacy and blood-brain barrier penetration.

Antisense oligonucleotides inhibit transcobalamin receptor activity to arrest tumor proliferation while sparing normal cells.

Modified FGF-P peptides resolve stability-reliability contradictions to reduce gastrointestinal toxicity and increase survival rates.

Formula I compounds inhibit inositol monophosphatase to reduce impulsive behaviors, avoiding lithium toxicity and side effects.

A covalent drug-polymer conjugate enables controlled release via intramolecular nucleophilic substitution.

A neuronal reprogramming system uses Ascl1, Brn2, Myt1l, and NeuroD1 to convert somatic cells into induced neurons.

Controlled hydrolysis yields silk peptides that reduce side effects while treating multiple brain diseases.

A monolithic oral dosage form uses specific emulsifiers and retardants to manage modified release profiles.

Annexin A5 converts secondary deleterious events into protective outcomes, reducing diffuse axonal injury and improving neurological recovery.

Composite electrospun nanofibers resolve the trade-off between mechanical strength and biochemical guidance in nerve conduits.

Establishing Master and Working Cell Banks expands Mesenchymal Stem Cell quantities while maintaining viability through optimized cryopreservation.

Replacing IRES elements with fusion proteins in lentiviral vectors to boost dopamine synthesis efficiency.

Elymus repens extracts supply vitamin B12 to address deficiency in vegans.

TRPM8 agonists reduce excitotoxicity without interfering with normal glutamate action.

Conjugating antigens to CLEC9a antibodies targets CD8+ dendritic cells, resolving specificity bottlenecks in cross-presentation therapies.

Tigernut extract and mangiferin combination enhances gamma wave activity to provide sustained attention without caffeine-induced nervousness.

Regional tau-PET SUVR analysis identifies preclinical disease and monitors therapy response to reduce diagnostic delay.

Covalent conjugation of dextrorphan with oxoacids and polyethylene glycols creates stable prodrug intermediates that resist non-oral abuse routes.

CIC-1 ion channel inhibitors recover neuromuscular transmission by blocking chloride flow, addressing side effects from traditional AChE treatments.

Peptide compounds modulate PSD-95 signaling via high-affinity PDZ3 binding, reducing neuroinflammation and excitotoxicity.

Acidic extracts containing 2,5-piperazinedione prevent sedimentation and preserve flavor stability in acidic beverage formulations.

Anti-TREM1 antibodies neutralize TREM1-mediated cytokine release and neurotoxicity in ALS and Alzheimer's disease models.